

HOUSE BILL 1469

J5

6lr2735

By: **Delegate Cullison**

Introduced and read first time: February 13, 2026

Assigned to: Health

A BILL ENTITLED

1 AN ACT concerning

2 **Health Insurance – Workgroup to Study the Definition of Specialty Drug**

3 FOR the purpose of requiring the Maryland Insurance Administration to convene a
4 workgroup to study a certain definition of “specialty drug” in a certain manner and
5 make a recommendation for a new definition of “specialty drug”; and generally
6 relating to health insurance and specialty drugs.

7 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
8 That:

9 (a) The Maryland Insurance Administration shall convene a workgroup to study
10 the definition of “specialty drug”.

11 (b) The workgroup shall consist of the following members:

12 (1) two representatives of pharmacy benefits managers;

13 (2) two representatives of independent pharmacists;

14 (3) one representative of a carrier that owns a pharmacy benefit manager;

15 (4) one representative of a carrier that does not own a pharmacy benefit
16 manager;

17 (5) one representative of a managed care organization;

18 (6) one representative of a hospital; and

19 (7) one representative of a health care provider that is not a hospital.

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 (c) The workgroup shall study the definition of “specialty drug” established under
2 § 15–847 of the Insurance Article to:

3 (1) determine:

- 4 (i) which stakeholders benefit from the definition;
- 5 (ii) which stakeholders are disadvantaged by the definition;
- 6 (iii) how each stakeholder group applies the definition;
- 7 (iv) the impact of the definition on patients; and
- 8 (v) any unintended consequences of the definition;

9 (2) compare the definition to other definitions of “specialty drug” used in:

- 10 (i) federal law;
- 11 (ii) other states’ laws, and
- 12 (iii) international law; and

13 (3) make a recommendation for a new definition of “specialty drug” that is
14 in the best interest of patients and all stakeholders in the State.

15 (d) On or before January 1, 2027, the Maryland Insurance Administration shall
16 report the workgroup’s findings and recommendations to the Governor and, in accordance
17 with § 2–1257 of the State Government Article, the General Assembly.

18 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July
19 1, 2026. It shall remain effective for a period of 1 year and, at the end of June 30, 2027, this
20 Act, with no further action required by the General Assembly, shall be abrogated and of no
21 further force and effect.